Tag: Pharmaceutical Company

Browse exclusive Tags!

Outlook Therapeutics Faces Potential Lawsuit Over Misleading Statements – Investors Urged to Act

Outlook Therapeutics faces possible lawsuit over allegations of misleading statements. Investors urged to contact Faruqi & Faruqi for more info.

Lyme Disease Vaccine Lymerix Returns, Rekindling Hope

Get hopeful about the return of the Lyme disease vaccine, Lymerix. With proven efficacy and significant effectiveness, this vaccine could make a big impact on reducing the prevalence of the illness.

Mallinckrodt Sets $1.9B Debt Reduction Plan in Motion with Chapter 11 Filing, US

Global pharmaceutical company Mallinckrodt takes significant step in reducing debt and addressing opioid crisis through Restructuring Support Agreement.

Eli Lilly Stock Surges on Strong Earnings and Growing Weight-Loss Drug Success

Eli Lilly's stock surges on strong earnings and weight-loss drugs. Can it meet high expectations in upcoming earnings report?

Popular

Eli Lilly’s Potential for the Next Ozempic: A Smart Stock Buy?

Discover how Eli Lilly is becoming a major player in weight loss and diabetes treatments, with its drug retatrutide showing impressive results.

Incyte Corp Q2 Profit and Revenue Beat Estimates on Strong Demand for Jakafi and Opzelura

Incyte Corp exceeds expectations with strong Q2 results driven by high demand for Jakafi and Opzelura drugs. Positive forecast revision and stock rise.

Roivant Sciences’ Stock Rises 3.7% in Pre-Market as Losses Narrow

Roivant Sciences beats expectations with strong Q4 results, driving a 3.7% stock price increase. Impressive revenue growth in immunology, oncology, hematology, and dermatology.

Delhi High Court Asks Centre’s Opinion on Plea Challenging Ban of FDC Medications

The Delhi High Court has asked for the government's response on a pharmaceutical company's plea on the ban of FDC drugs. Glenmark Pharmaceuticals challenges the ban on manufacturing, selling, and distributing certain FDC drugs for human use. The ban was announced on June 2 due to no therapeutic justification and potential risks. The court will hear the matter on July 3.

Subscribe

spot_imgspot_img